Cardiovascular complications of Bruton's Tyrosine Kinase inhibitors (BTKi) Bruton Tyrosine Kinase (BTK) inhibitors have been approved and is an advanced treatment for hematological malignancies. However, one potential side effect of this treatment is an increased risk of cardiac arrhythmias, which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTK inhibitors. In this new observational research study, doctors at the National Institutes of Health (NIH) hope to identify and monitor cardiac rhythms to understand arrhythmias in patients on BTK inhibitors.
Study Design:
- Medical history and physical exam
- Blood draws and an electrocardiogram (ECG)
- Exercise stress test
- A 14-day continuous cardiac monitoring evaluation
- KardiaMobile will be provided to patients with smart phones who will obtain a cardiac tracing of tachycardia, palpitations, skipped beats or pauses, near loss of consciousness, loss of consciousness, excessive shortness of breath, or chest pain
You can participate in this study if you:
- Are 18 or older
- Are currently receiving or planning to receive a BTK inhibitor
- Are able to tolerate exercise or pharmacologic cardiac testing
- Do not have a cardiac condition including myocardial infarction or decompensated heart failure within the past 3 months
- Are not pregnant or breastfeeding
Your participation is at no cost, and travel assistance may be available.
The NIH Clinical Center, America's Research Hospital is located in Bethesda, MD on the Metro red line (Medical Center stop).
For more information:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
TTY users dial 7-1-1
Email: ccopr@nih.gov
Or go online:
https://bit.ly/414oewX
Refer to NIH study # 000923-H
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Heart, Lung and Blood Institute (NHLBI)